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Abstract
Background: Recent case reports suggest that benfluorex, a fenfluramine derivative used in the management of overweight
diabetic patients and dyslipidemia, is associated with cardiac valve regurgitation.
Methods: We conducted a case-control study. Eligible patients were those admitted in the cardiology or the cardiac surgery
units of our hospital between January, 1
st 2003 and June 30
th 2009, with mitral insufficiency diagnostic codes (ICD-10 I340
and I051). Patients with either a primary cause (degenerative, known rheumatic heart disease, infectious endocarditis,
congenital, radiation-induced valvular disease, associated connective and/or vasculitis disease, trauma, tumor) or a
secondary (functional) cause were considered as having an ‘‘explained’’ mitral regurgitation. Other patients were considered
as having an ‘‘unexplained’’ mitral regurgitation and were included as cases. For each case, two controls were matched for
gender and for the closest date of birth, among a list of patients with an ‘‘explained’’ mitral regurgitation. Drug exposures
were assessed blindly regarding the case or control status, through contacts with patients, their family and/or their
physicians.
Results: Out of the 682 eligible patients, 27 cases and 54 matched controls were identified. The use of benfluorex was
reported in 22 patients: 19 of the 27 cases, versus 3 of the 54 controls, odds-ratio 17.1 (3.5 to 83), adjusted for body mass
index, diabetes and dexfenfluramine use.
Conclusion: The use of benfluorex is associated with unexplained mitral regurgitation.
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Introduction
Exposure to fenfluramine and dexfenfluramine has been
associated with the occurrence of cardiovascular side effects,
including pulmonary arterial hypertension (PAH) and valvular
heart disease [1,2]. As a consequence, these two anorexigens were
withdrawn from drug market in 1997. Meanwhile, involvement of
5-HT2B receptors in fenfluramine-induced valvular heart disease
has been demonstrated, and the medical community was warned
of the possible fenfluramine-like cardiovascular side effects of
potent 5-HT2B receptor agonists [3]. Recently, we reported five
PAH cases and one severe valvular heart disease in patients
exposed to benfluorex [4], a fenfluramine derivative [5]. This drug
has been marketed since 1976 in Asia, Europe and South America
and administered for the treatment of overweight diabetic patients
and dyslipidemia. It is still the object of active research, including
two ongoing clinical trials (WHO International Clinical Trials
Registry Platform). As it was currently used by about 300,000
patients each year in France according to the national insurance
database, our observations, added to two previous case reports in
the literature [6,7], prompted us to conduct a retrospective case-
control study in order to examine the possible association of
benfluorex exposure with mitral regurgitation, one of the
cardiovascular conditions described in patients exposed to
fenfluramine derivatives [2,8].
Methods
We designed a retrospective case-control study. Eligible patients
were those admitted to either the cardiology or cardiac surgery
units of Brest University Hospital between January 1
st, 2003 and
June 30
th, 2009. Using our institution patient discharge data file,
we chose to focus on mitral regurgitation and retrieved patients’
charts with ‘‘non-rheumatic or rheumatic mitral (valve) insuffi-
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I340 and I051). The study was conducted according to French
regulations and approved by our institutional Ethics Committee
(Comite ´ d’e ´thique du CHRU de Brest). As requested by the Ethics
committee, a verbal consent was obtained prior to the phone
interview.
Ascertainment of disease
We classified the patients into two groups: with and without an
identifiable cause of mitral regurgitation.
The first group had a valvulopathy with a primary or secondary
cause recorded explicitly in the patient’s hospital file. Primary
cause was: either degenerative (mitral-valve prolapse with cordal
rupture, annular calcification), known rheumatic heart disease,
infectious endocarditis, congenital, radiation-induced valvular
disease, associated connective and/or vasculitis disease, trauma
or tumor. Secondary (functional) cause was defined by a
structurally normal mitral valve on echocardiography and the
presence of an underlying cardiomyopathy i.e. either dilated
cardiomyopathy responsible for a mitral annulus dilatation, or
ischemic left-ventricular remodeling or hypertrophic cardiomyop-
athy (primary obstructive cardiomyopathy or secondary to severe
aortic restriction) responsible for loss of coaptation. The ischemic
origin of the cardiac disease had to be documented by a coronary
angiography.
The second group included patients without any of these
etiologies, who were considered as having an ‘‘unexplained’’ mitral
regurgitation.
A research nurse was trained to screen patients’ charts: medical
history, echocardiography report, operative report in patients who
underwent valvular heart surgery, and histological report. If one of
the conditions mentioned above was listed, the patients were
classified as having an explained mitral regurgitation. Whenever
the information was unclear, two physicians (YE, YJ) reviewed the
data in order to classify the patients regarding valvular heart
disease etiology.
Selection of cases and controls
All patients classified as having an unexplained mitral
regurgitation were included as cases. For each case, a list of
potential controls was established from the roster of patients with
an explained mitral regurgitation. This list included all patients of
the same gender, hospital admission unit, and admission date
(within a one year period of the case’s admission date). Finally,
from this list, we selected as controls the two patients with the
closest date of birth to that of the case.
Ascertainment of drug exposure
The assessment of drug exposure was performed similarly for
cases and controls. Independently trained research nurses unaware
of the patient’s status (case or control) called each patient and his/
her family physician to collect information about associated
conditions (diabetes, obesity, dyslipidemia) and drug exposure
(amphetamine derivatives), using a semi-structured questionnaire.
Physicians were asked to consult their patient’s files during the
telephone call. Information collected included the patient’s height,
weight (current and highest life-time weight) and associated
conditions. Patients and physicians were asked whether or not
the patient experienced weight-related issues, and whether or not
he/she ever used appetite suppressants, weight-loss drugs or
slimming diets. Current diabetes medications were recorded. All
amphetamine derivative brand names and international non-
proprietary names, including dexfenfluramine and benfluorex,
were listed during the interview, and patients were asked whether
or not they remembered having used one of these medications.
Whenever the patient or his/her physician disclosed any use of
benfluorex, information on the exposure period was collected. A
standardized case-report form was filled for each patient. In the
event of death, information was retrieved by interviewing the
patient’s relatives and family physician. Patients were considered
as exposed to benfluorex if the patient and/or the family physician
mentioned benfluorex use. All medical records were also checked,
and the mitral regurgitation diagnostic date was retrieved.
Data analysis
The characteristics of cases and controls were described using
mean and standard deviation for continuous variables, and
proportion for categorical variables. The proportions of exposed
patients among cases and controls were compared using a chi-
square test. The odds-ratio of the association between benfluorex
and unexplained mitral regurgitation was computed along with its
95% confidence interval (95% CI). A multivariate logistic
regression model was performed to cater for possible confounders:
diabetes and obesity. SPSS software was used in all data
processing.
Results
Between January 1
st, 2003 and June 30
th, 2009, 682 patients
were admitted at least once to the cardiology department or to the
cardiothoracic surgery unit of Brest University Hospital with non-
rheumatic or rheumatic mitral (valve) insufficiency. Mean age was
69.8 years (standard deviation 12.7 years), and 385 (56.5%) were
males. A total of 636 patients had an explained mitral
regurgitation, 27 were unexplained, and 19 patients (2.8%) were
unclassified because the information available for ascertainment
was not sufficient.
Thus, the final study sample comprised 81 patients. Twenty-
seven cases (i.e. all patients with unexplained mitral regurgitation)
and 54 gender-, admission unit-, admission date- and age-matched
controls, selected among the 636 patients classified as having
explained mitral regurgitation. The etiology of mitral regurgitation
for the controls patients is shown in Table 1. Two controls needed
to be replaced using a new selection, one because neither the
Table 1. Etiology of the mitral regurgitation in the 54 control
patients.
Etiology of mitral regurgitation N=54
Primary mitral regurgitation
Mitral valve prolapse with cordal rupture 19
Annular calcification 4
Known rheumatic heart disease 8
Infectious endocarditis 2
Congenital 3
Connective or vasculitis disease 1
Tumor 1
Secondary mitral regurgitation
Left ventricular dilatation 7
Ischemic left ventricular remodeling 6
Hypertrophic cardiomyopathy 3
Other secondary cause 0
doi:10.1371/journal.pone.0010128.t001
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ascertainment and the other due to a language issue.
The general characteristics of the cases and controls are
displayed in Table 2. Most of the patients were females (72 out
of 81, 89%). The cases had statistically a significantly higher body
mass index than controls: 30.8 kg/m
2 (standard deviation 8.1)
versus 25.2 kg/m
2 (SD 7.1), p=0.002, and were more prone to
diabetes: 37.0% versus 7.4%, p=0.002. At the time of the study,
15 patients (6 cases and 9 controls) had died. Ascertainment of
drug exposure could be performed in all patients from at least one
source (family physician) and information was available from both,
the patient (or proxies) and his/her family physician for 85% of the
cases and 85% of the controls. Information was provided by
proxies in 11% (3/27) of the cases and 13% (7/54) of the controls.
Eight of the 10 proxies were interviewed because the patient was
dead. There were three discrepancies in exposure assessment
between physicians and patients or proxies: one 84-year old
woman case, whose physician notified a long exposure to
benfluorex, was not able to confirm this information; two proxies
of control patients were not able to confirm the absence of
benfluorex use reported by the physicians. The last say pertained
to physicians in these three instances.
The use of benfluorex was reported in 22 patients: 19 of the 27
cases (70.4%), versus 3 of the 54 (5.6%) controls, odds-ratio 40.4
(95% confidence interval 9.7 to 168.3), p,0.001. This association
remained statistically significant after adjustment regarding body
mass index and diabetes: odds-ratios for benfluorex use, body mass
index and diabetes were 27.6 (95%Cl 6.1 to 124.6), 1.1 (95%CI:
1.0 to 1.2), and 1.9 (95%CI: 0.3 to 11.7), respectively. There was
no interaction between variables included in the logistic regression
model.
Overall, 28 patients were identified as users of amphetamine
derivatives. Among them, 22 were users of benfluorex, eight of
whom also reported a previous use of dexfenfluramine, and one of
biphetamine. The six remaining patients (who had never used
benfluorex) reported the use of dexfenfluramine alone (n=3),
clobenzorex (n=1), phenmetrazine (n=1), and an unspecified
amphetamine derivative (n=1). Further adjustment regarding
dexfenfluramine use or any amphetamine derivative use did not
alter the results: adjusted odds-ratio for benfluorex use 17.1
(95%CI 3.5 to 83.0) and 21.4 (95%CI 1.6 to 284.9), respectively.
Approximate exposure periods could be obtained in all users of
benfluorex. Patients and/or physicians reported the first use of
benfluorex before the diagnosis of mitral regurgitation in 18 out of
the 19 exposed cases. Among them, 17 were users of benfluorex
within the two years before the diagnosis of mitral regurgitation.
For all three controls exposed to benfluorex, the reported first use
took place after mitral regurgitation was diagnosed. Thus, if we
restrict the analysis to exposure occurring before diagnosis of
mitral regurgitation, no control patients were exposed (vs 18/27
cases, p,0.0001).
Discussion
In this case-control study, exposure to benfluorex was reported
in 70% of patients with unexplained mitral regurgitation. When
compared to a control group of patients with explained mitral
regurgitation, a strong association was observed between ben-
fluorex use and unexplained mitral regurgitation: odds-ratio 40.4
(95% confidence interval 9.7 to 168.3). This association was
independent from diabetes, body mass index and other amphet-
amine derivatives use, including dexfenfluramine.
We focused on mitral regurgitation, although other valvular
damage, such as aortic regurgitation has been observed with
previously investigated fenfluramine derivatives [8]. This choice
was based on the fact that almost all the patients in the study by
Connolly et al. had mitral regurgitation and mitral regurgitation is
a well-characterized condition which is more common than other
valvular regurgitations [2,9]. We selected as cases patients with
unexplained mitral regurgitation in order to focus on patients with
unrecognized risk factors. We selected as controls patients with an
explained mitral regurgitation in order to ensure that cases and
controls came from the same population. The selection of controls
from patients with ‘‘explained’’ mitral regurgitation has both
strengths and weaknesses. Whether selection of controls among
patients with the same disease as cases is appropriate or not is a
matter of debate. In fact some of the risk factors for ‘‘explained’’
mitral regurgitation may be only weakly associated but any
erroneous assumptions in these regards would be expected to
dampen any true association. Selecting controls from the general
population with diabetes or with metabolic syndrome would have
been a far longer process.
We observed a small proportion of unexplained mitral
regurgitation, a clinical picture not mentioned in textbooks or
in the recent review by Enriquez-Sarano et al [10]. This is
consistent with our hypothesis that the possible association
between benfluorex exposure and mitral regurgitation should
be preferably detectable in the subgroup of patients with no
identified risk factor for mitral regurgitation. The classification of
mitral regurgitations regarding unexplained and explained
Table 2. General characteristics of cases and controls.
Characteristics, m: mean, SD: standard deviation Cases (n=27) Controls (n=54) p-value
Age, years, m (SD) 60.9 (11.5) 63.8 (11.6) 0.29
Female gender, n (%) 24 (88.9) 48 (88.9) 1.00
Body mass index, kg/m
2, m (SD) 30.8 (8.1) 25.2 (7.1) 0.002
Diabetes, n (%) 10 (37.0) 4 (7.4) 0.002
Mitral valvular surgery, n (%) 14 (51.9) 26 (49.1) 0.81
Deceased, n (%) 6 (22.2) 9 (16.7) 0.54
Interview of both patient (or relative) and GP 23 (85) 46 (85) 1.00
Dexfenfluramine use 9 (33.3) 2 (3.7) 0.001
Benfluorex use 19 (70.4) 3 (5.6) ,0.001
Odds-ratio (95% CI): 40.4 (9.7 to 168.3)
doi:10.1371/journal.pone.0010128.t002
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was impossible to achieve this in only 2.8% of patients.
Classification bias is unlikely to have occurred since the whole
processing was blinded to drug exposure. Patients were identified
through ICD-10-CM codes, irrespective of the severity of mitral
regurgitation, and it is difficult to assess this severity retrospec-
tively. However, a mitral regurgitation which is given a diagnosis
code in the hospital discharge file is more than likely to be
clinically significant. Moreover, a mitral surgical procedure was
necessary in half of the cases and the controls.
Benfluorex has been marketed in France since 1976; hence
some patients may have forgotten a former use of the medication.
However, we asked physicians to check each patient’s file for all
prior medication use. Because of the retrospective design of the
study, precise timing, dose and duration of exposure were not
always available, and we could not study the dose-effect
relationship. We have focused our main analysis on the use or
non-use of benfluorex, without taking into account the timing of
the exposure because the data on timing of use and its relation to
the exact date of diagnosis was uncertain for some patients. If we
limit the exposure to those occurring before the diagnosis of mitral
regurgitation, the odds ratio is increased to infinity. Information
on drug exposure was collected blindly from the patient’s status. A
recall bias is unlikely to have occurred since firstly, cases and
controls shared the same cardiac condition, and secondly the
association between benfluorex and mitral regurgitation was not
known. Some patients were also previous users of amphetamine
derivatives, mainly dexfenfluramine, and this could have contrib-
uted to valve disease. However, dexfenfluramine was withdrawn
from the market in 1997, six years before the beginning of our
study inclusion period. Therefore, dexfenfluramine is unlikely to
have played a role among our patients especially as the short-term
effect of dexfenfluramine on regurgitation has been suggested [6].
Moreover, in our study, the association between benfluorex and
unexplained mitral regurgitation was independent from dexfen-
fluramine exposure.
In their landmark study published in 1997, Connolly et al.
identifying valvular heart disease in 24 women treated with
fenfluramine-phentermine who had no history of cardiac disease,
raised the hypothesis of an association between such drug intake
and valvular heart disease [2]. One year later, the results of three
studies conducted in different settings with different designs were
made available: two case-control studies included patients who
received fenfluramine derivatives and their matched controls
[11,12]; one trial evaluated the effects of two forms of dexfen-
fluramine and placebo [13]. All three studies, though differing
with regard to the strength of the statistical association and clinical
significance, supported an association between the use of
fenfluramine derivatives and valvular heart regurgitation. Simi-
larly, following the identification of valvular heart disease in three
patients taking pergolide [14], another serotoninergic medication,
two case-control studies reported an association between the use of
dopamine agonists, pergolide and cabergoline, and valve regur-
gitation [15,16]. Meanwhile, evidence for possible involvement of
5-HT2B receptors in the cardiac valvular heart disease associated
with ergot derivatives, dopamine agonists and amphetamine
derivatives (fenfluramine and methylenedioxymethamphetamine)
has been provided [17]. Consequently, practitioners were warned
of the possible side effects of potent 5-HT2B receptor agonists
[3,18]. Other drugs belonging to the same class would be expected
to carry the same risks, and indeed, with a different patient
selection, our study strongly suggests that benfluorex, a fenflur-
amine derivative marketed in several countries, is associated with
valvular heart disease. Arguments in favor of a causal association
are the biological mechanism (5-HT2B receptor agonism), the
strength and significance of the association, and its independence
from other factors.
Based on this study and on the analysis of the situation in
France, the French authorities have withdrawn benfluorex from
the national market on November 26, 2009 [19].
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